Day One results, progress report

 PDUFA target action date for tovorafenib NDA in relapsed or progressive pLGG remains set for April 30, 2024

Phase 2 FIREFLY-1 tovorafenib registrational data published in Nature Medicine

Ended 2023 with $366.3 million in cash, cash equivalents and short-term investments providing runway into 2026

https://www.globenewswire.com/news-release/2024/02/26/2835523/0/en/Day-One-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Corporate-Progress.html